[World First] U-Factor® liquid used in ALS (Amyotrophic Lateral Sclerosis) prospective intervention study results presented at academic conference

U-Factor Holdings Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; Representative Director: Hidehiro Ijima; hereinafter, "the Company") announced that Dr. Yasuhiro Seta, Director of Hitonowa Medical (outside executive officer of the Company), presented the results of a prospective intervention study on ALS (Amyotrophic Lateral Sclerosis) using human dental pulp-derived stem cell conditioned medium (hereinafter, "U-Factor® liquid") developed by our group, at the "25th Annual Meeting of the Japanese Society for Regenerative Medicine" held on March 20, 2026. This study (jRCTs031230731) is a groundbreaking, world-first achievement demonstrating new treatment possibilities for improving function in the intractable disease ALS. 1. Presentation content: ALS (Amyotrophic Lateral Sclerosis) is a progressive intractable disease in which motor neurons degenerate, leading to muscle weakness throughout the body, and the establishment of a fundamental treatment method is eagerly awaited worldwide. In this academic presentation, the safety and potential for functional improvement were reported based on the results of a prospective intervention study using U-Factor® liquid for this difficult problem. 2. What is U-Factor® liquid? It is a supernatant liquid produced during the culture of human dental pulp-derived stem cells. It is rich in "neurotrophic factors" that may contribute to the improvement of ALS symptoms and has neuroprotective and immunomodulatory effects. Since the cells themselves are not transplanted, it is attracting attention as a next-generation regenerative medicine that is simple and highly safe. 3. Research points: Completion of the world's first prospective intervention study: A "prospective intervention study" based on medical evidence was conducted for the first time in the world for systemic administration of U-Factor® liquid to ALS patients. Verification of safety with 12 weeks of continuous administration: 120 mL of stem cell conditioned medium was intravenously administered once a week for a total of 12 weeks to 8 patients. No serious side effects were observed, suggesting clinical safety. Signs of improvement in respiratory function and suppression of progression: As a result of efficacy evaluation (ALSFRS-R, grip strength, %FVC), improvement in respiratory function (%FVC) and suppression of progression were observed in some cases, suggesting the possibility of functional recovery. 4. Future outlook: Based on the knowledge gained from this study, our group will proceed with the optimization and further verification of stem cell conditioned medium therapy. We are committed to accelerating social implementation so that it can be established as a standard treatment method as soon as possible, and to delivering new treatment options to patients suffering from intractable diseases, including ALS (Amyotrophic Lateral Sclerosis), and their families. 5. Company profile: U-Factor Holdings Co., Ltd. Location: 6-4-6 Kojimachi, Chiyoda-ku, Tokyo 102-0083 Representative: Hidehiro Ijima, Representative Director Established: February 4, 2026 Business activities: Formulation of group-wide management strategies and management https://u-factor.com Hitonowa Medical Location: K, Plaza Building 2F, 1-7 Rokubancho, Chiyoda-ku, Tokyo 102-0085 Representative: Yasuhiro Seta, Director Established: October 2020 Business activities: Providing medical care that "stays close to patients and faces illness together" with a focus on "regenerative medicine x intractable diseases" https://hitonowa-medical.com/ [Contact for this release] U-Factor Holdings Co., Ltd. Public Relations TEL: 03-5357-1580 Email: info@u-factor.com